345310-98-7

Usage

Uses

Used in Pharmaceutical Industry:
Piperazinone, 1-(2-pyridinyl)(9CI) is used as a chemical intermediate for the synthesis of various drugs, playing a crucial role in the development of new medicinal compounds.
Used in Antipsychotic Drug Development:
In the field of psychiatry, Piperazinone, 1-(2-pyridinyl)(9CI) is used as a potential antipsychotic agent, being studied for its capacity to alleviate symptoms associated with psychotic disorders.
Used in the Treatment of Central Nervous System Disorders:
Piperazinone, 1-(2-pyridinyl)(9CI) is also being investigated for its potential therapeutic effects in the treatment of various central nervous system disorders, highlighting its versatility in medicinal chemistry.
Used as an Enzyme Inhibitor:
Furthermore, Piperazinone, 1-(2-pyridinyl)(9CI) has been explored for its ability to inhibit specific enzymes, which could have implications in the treatment of certain diseases where enzyme activity is a contributing factor.

InChI:InChI=1/C9H11N3O/c13-9-7-10-5-6-12(9)8-3-1-2-4-11-8/h1-4,10H,5-7H2

Upstream product

• 1279815-59-6 1,1-dimethylethyl 4-(2-pyridinyl)-3-oxo-1-piperazinecarboxylate 
• 109-04-6 2-bromo-pyridine 
• 345310-96-5 2-(2-hydroxyethylamino)-N-pyridin-2-yl-acetamide 
• 998-40-3 tributylphosphine 
• 870-50-8 di-tert-butyl (E)-azodicarboxylate 
• 374795-58-1 4-phenylmethyl-1-(2-pyridinyl)piperazin-2-one 

Relevant academic research and scientific papers

Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

A series of β-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)- butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development.

HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS

Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein a, b, A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition

The present invention provides a compound of formula (I) in which R1 is generally hydrogen or CF3, R2 is generally hydrogen, W is a cyclic amine, a heterocycle or a group L-Y-X where L-Y is a linking portion and X is generally an aromatic or non-aromatic heterocycle, alkyl or alkylcarbonyl and Z is generally a heterocycle such as 5-methylisoxazol-3-yl, and pharmaceutically acceptable salts thereof for enhancing cognition in conditions such as Alzheimer's Disease, pharmaceutical compositions comprising them, their use for manufacturing medicaments and methods of treatment using them.

Cyclohexane derivatives and their use as therapeutic agents

The present invention relates compounds of formula (I), wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of formulae: (a), (b), (c), (d), and (e); and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R17, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.